I have read this book since my SHO days, when the first edition was published in 1996, and still enjoy reading every new edition. This is a concise, pocket-sized book which is designed to provide a rapid update on what...
This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....
Urologists are always trying to identify risk factors for prostate cancer (CaP). This population-based study is from Ontario, Canada. The study sample comprised nearly 300,000 men who underwent vasectomy and an equal number who did not. The primary outcome was...
Men with localised prostate cancer have traditionally required whole gland treatment involving radical prostatectomy or radical radiation treatment, independent of disease location and size. Increasing evidence supports the use of active treatment only in those men diagnosed with prostate cancer...
MOWOOT II is an intermittent colonic exo-peristaltic therapy system for intestinal transit disorders, such as slow transit constipation. MOWOOT II utilises advanced pneumatic technology to treat and prevent chronic constipation without laxatives, enemas...
Focal Healthcare, an innovator of image-guided prostate cancer technology, has received CE Mark for its Fusion BxTM 2.0 prostate fusion biopsy solution.
The Covid-19 pandemic has led to around 52,000 (28%) fewer urgent prostate cancer referrals in England alone, according to statistics shared by Prostate Cancer UK. It’s estimated that more than 8,600 fewer men started treatment for...
KOELIS Trinity® is a fully integrated mobile fusion imaging platform designed for personalised prostate care. Uniquely equipped with 3D ultrasound probes and KOELIS® patented Organ-Based Tracking Fusion® technology, KOELIS Trinity® brings maximum...
A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...
Case 1 A 65-year-old man is referred to your two-week wait (2WW) clinic with a PSA of 7.0ng/mL. He has no lower urinary tract symptoms (LUTS), no past medical history, no family history of prostate cancer (PCa) and his performance...
The Memorial Sloan Kettering Cancer Center (MSKCC) developed prostate cancer screening recommendations first in 2011 as a response to three limitations of previous screening guidelines: insufficient evidence base, failure to link screening with treatment, and lack of risk stratification. To...
Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home. An innovative new study launched this week,...